Catalyst Event
Ionis Pharmaceuticals Inc (IONS) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/28/2026, 12:00:00 AM
Partner GSK announced positive pivotal Phase 3 data for bepirovirsen in chronic hepatitis B, showing a statistically significant 19% functional cure rate. The results were published in the New England Journal of Medicine, and first regulatory decisions are anticipated in Q3 2026.
Korean Translation
파트너사 GSK, 만성 B형 간염 치료제 베피로비르센(bepirovirsen)의 주요 임상 3상 시험에서 통계적으로 유의미한 19%의 기능적 완치율을 보인 긍정적 데이터를 발표함. 결과는 뉴잉글랜드 저널 오브 메디슨에 게재되었으며, 최초 규제 당국 결정은 2026년 3분기로 예상됨.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM